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beneﬁt of new treatments for BC is directly measurable at the
national level.
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OBJECTIVES: To calculate the total per patient cost of prostate
cancer (PCa) treatment by stage in the 1st year following diagno-
sis in 5 European countries. METHODS: IMS Oncology
Analyzer (OA), a survey-based data collected from urologists,
radiologists, and oncologists between 2002–2006 provided data
on diagnostic interventions and initial treatment for 10,576
patients treated in hospitals for UK, Germany, France, Italy and
Spain. A costing model combined the data with local expert
opinion and published data on resource use and unit costs from
published sources to calculate total per patient costs by stage.
Diagnostic costs, ﬁrst surgery, radio- and chemotherapy costs, if
any, were included. Cost of 1st-line hormonal therapy, with pos-
sibly was also included. Relapse and mortality was factored
into the model. Total direct medical costs of initial treatments
following diagnosis per patient were calculated for all stages.
RESULTS: Majority of men across countries were diagnosed in
Stage II. As initial treatment following diagnosis, across all
stages, radiation therapy (EBT + brachytherapy) was used most
frequently across countries, ranging from 42% (France) to
21.5% (Germany). Use of chemotherapy was low. Total per
patient direct costs following diagnosis averaging all stages were
€4057, €3256 €3171 (exchange rate conversion), €5226 and
€5851 for Germany, Spain, UK, Italy and France, respectively.
Surgeries were the largest cost component in all countries except
for the UK and Germany. In Germany hormone therapy repre-
sents a similar cost to surgery; in the UK where radiation therapy
had the highest cost proportion. CONCLUSIONS: In this ﬁrst
study quantifying the cost of PCa treatment in ﬁve European
countries using similar methods and source across countries
found similar total per patient cost estimates, although different
treatment patterns and types of costs by country. Given the
number of new cases diagnosed in Europe, these estimates
suggest a large total spending on the disease.
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OBJECTIVES: Although years of potential life lost (YPLL) and
mortality-related productivity costs comprise a substantial
portion of the burden of cancers where HPV may be a risk factor
for carcinogenesis (henceforth called HPV-associated cancers),
estimates of these costs are limited. We estimated the mortality-
related burden (in terms of YPLL and productivity costs) of
HPV-associated cancers and all malignant cancers in the United
States in 2003. METHODS: We used 2003 national mortality
data and US life tables to estimate YPLL for HPV-associated
cancers and all malignant cancers. YPLL was estimated by use of
the life expectancy method. We used the human capital approach
to estimate the value of the expected future lifetime productivity
losses due to premature deaths from HPV-associated cancers and
all malignant cancers. Indirect mortality costs were estimated
as the product of the number of deaths and the expected value
of individuals’ future earnings, including an imputed value
of housekeeping services. RESULTS: In 2003, HPV-associated
cancers accounted for 181,026 in YPLL, which represent 2.4%
of the estimated 7.5 million YPLL attributable to all malignant
cancers in the United States. The average number of YPLL was
21.8 per HPV-associated cancer death and 16.3 per death to
overall malignant cancers. Overall, HPV-associated cancers had
the largest relative contribution to YPLL in 30–34 year-old
females. The lifetime productivity cost due to mortality in 2003
was $3.7 billion for HPV-associated cancer mortality and $133.5
billion for overall malignant cancer mortality. CONCLUSIONS:
HPV-associated cancers impose a considerable burden in terms
of premature deaths and productivity losses. Quantifying the
burden of these HPV-associated cancers mortality in the popu-
lation may provide useful information for understanding the full
potential beneﬁts of prevention efforts.
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OBJECTIVES: To estimate the cost-effectiveness of Reyataz®
versus Kaletra® in treatment-naïve HIV-1 patients in Italy.
METHODS: For this purpose a life time Markov model was
developed with a cycle length of one year. The model included the
following health states; 1st, 2nd and 3rd line treatment and within
these treatment lines patients could suffer from an MI, stroke or
angina. Treatment switch transition probabilities were derived
from a 48 week randomized trial and event probabilities were
derived from the Framingham risk equations and the 48 week
trial. Diarrhea was included as a disutility. Variables that differed
between the two treatment arms were pharmaceutical treatment
costs, lipid proﬁle, probability to switch 1st line treatment, mor-
tality and incidence of diarrhea. The analysis was conducted
from a third-party payer perspective. Direct costs inside the
health care system were included. Outcomes were reported as
cost per (quality adjusted) life year gained. To determine the
robustness of the model and the impact of uncertainty, uni- and
multivariate sensitivity analyses were carried out. RESULTS: In
the base case analysis Reyataz® saved 0.07 [-0.50, 0,83] life
years, 0.12 [-0.31, 0.85] QALYs and -€508 [-€88,264, €19,424]
costs. The resulting ICER and ICUR were dominant for
Reyataz®, e.g. cost saving and more effective. Probabilistic sen-
sitivity analyses showed that Reyataz® has 0.80%, 16.70%,
10.30% and a 72.20% probability to be in NW, SW, NE and SE
quadrant of cost-effective scatter plot respectively, and a 94.1%
probability to be cost-effective at a WTP of €20,000. The univari-
ate sensitivity analysis showed that the results were especially
sensitive to changes in the cost of second and third line treatment
and switching treatment probabilities. CONCLUSIONS: The
present model suggests that Reyataz® has a favourable cost-
effective ratio in the treatment of treatment naïve HIV-I patients.
Sensitivity analysis showed that these results were stable.
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